Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
Mo | Alpha Teknova (TKNO) Surged Following Accelerated Demand | 2 | Insider Monkey | ||
01.09. | Does Alpha Teknova (TKNO) Have Meaningful Growth Opportunities? | 2 | Insider Monkey | ||
08.08. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
10.07. | Alpha Teknova files $225M mixed securities shelf | 4 | Seeking Alpha | ||
23.06. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.05. | Alpha Teknova Q1 2025 slides: improved margins despite mixed revenue performance | 2 | Investing.com | ||
08.05. | Alpha Teknova GAAP EPS of -$0.09, revenue of $9.8M | 2 | Seeking Alpha | ||
25.04. | Alpha Teknova, Inc.: Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 | 1 | GlobeNewswire (USA) | ||
04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 481 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 6,110 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
QIAGEN | 42,105 | +0,59 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
NUVALENT | 97,18 | -0,81 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
COGENT BIOSCIENCES | 15,860 | -2,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
RANI THERAPEUTICS | 2,880 | 0,00 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 189,94 | +8,41 % | Praxis Precision Medicines prices $525M public offering | ||
SUMMIT THERAPEUTICS | 18,780 | -6,24 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 20,640 | -1,15 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
DISC MEDICINE | 86,15 | -1,17 % | Disc Medicine Inc: Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National... ► Artikel lesen | |
EVOTEC | 6,822 | +1,91 % | Evotec Aktie: Entscheidende Marke bei 7 Euro - dann hoch auf 10 Euro? | © Foto: fnNach monatelanger Talfahrt hat sich die Evotec-Aktie stabilisiert und sammelt Kraft für einen möglichen Befreiungsschlag. Die entscheidende Frage lautet: Schafft es der Titel, die psychologisch... ► Artikel lesen | |
BIONTECH | 92,45 | -0,16 % | Diese Biotech-Aktie könnte Big Pharma das Fürchten lehren - mit einem oralen Abnehm-Blockbuster und Milliardenpotenzial bei MS! | Anzeige / WerbungWährend die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung... ► Artikel lesen | |
LENZ THERAPEUTICS | 33,510 | -7,69 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
BEAM THERAPEUTICS | 29,890 | -2,42 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
SIONNA THERAPEUTICS | 42,630 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis | SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 23,150 | +7,62 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report |